- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Allotransplantation.
Displaying page 1 of 1.
EudraCT Number: 2007-001052-39 | Sponsor Protocol Number: DSHNHL2006-1A | Start Date*: 2010-04-14 |
Sponsor Name:University Medicine Goettingen | ||
Full Title: Auto-versus Allotransplantation in T-NHL - Autologous or allogeneic transplantation following conventional chemotherapy in younger patients (18-60 yrs.) with mature (peripheral) T-cell lymphoma | ||
Medical condition: Peripheral (mature) T-cell lymphoma, first diagnosis, ALK-negative | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-000693-18 | Sponsor Protocol Number: ActD-AML-PG01 | Start Date*: 2014-05-27 | |||||||||||
Sponsor Name:Dipartimento di Medicina, Università di Perugia | |||||||||||||
Full Title: A PHASE II STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF ACTINOMYCIN D IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH NUCLEOPHOSMIN (NPM1) GENE MUTATION | |||||||||||||
Medical condition: Relapsed/refractory acute myeloid leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002244-86 | Sponsor Protocol Number: REP0113 | Start Date*: 2013-07-11 |
Sponsor Name:Dompé s.p.a. | ||
Full Title: Effect of reparixin on long-term outcomes after pancreatic islet transplantation in type 1 diabetes mellitus patients. A non-interventional, monocentre study to extend up to 3 years the follow-up ... | ||
Medical condition: patients who have received pancreatic islet transplantation | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004101-26 | Sponsor Protocol Number: TJB0601P1 | Start Date*: 2006-12-13 | |||||||||||
Sponsor Name:CHU Sart-Tilman | |||||||||||||
Full Title: Mesenchymal stem cell infusion as prevention for graft rejection and graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning: a pilot study | |||||||||||||
Medical condition: Patients with hematological malignancies not candidate for conventional allogeneic transplantation because of age or comorbidities. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000889-29 | Sponsor Protocol Number: CLNP023X2202 | Start Date*: 2018-12-13 |
Sponsor Name:Novartis Pharma AG | ||
Full Title: An open-label, non-randomized study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy | ||
Medical condition: C3 glomerulopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) FR (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-014980-38 | Sponsor Protocol Number: TJB0909P1 | Start Date*: 2010-07-06 | |||||||||||
Sponsor Name:CHU de Liège | |||||||||||||
Full Title: Co-transplantation of mesenchymal stem cells and HLA-mismatched allogeneic hematopoietic cells after reduced-intensity conditioning: a phase II randomized double-blind study. | |||||||||||||
Medical condition: Hematological malignancies confirmed histologically and not rapidly progressing: - AML in Complete Remission; - ALL in Complete Remission; - CML unresponsive/intolerant to Imatinib but not in b... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024297-19 | Sponsor Protocol Number: TJB1016P1 | Start Date*: 2011-09-13 | ||||||||||||||||
Sponsor Name:CHU de Liege | ||||||||||||||||||
Full Title: Allogeneic hematopoietic cell transplantation from HLA-matched donors after reduced-intensity conditioning: a phase II randomized study comparing 2 GVHD prophylaxis regimen | ||||||||||||||||||
Medical condition: Hematologic malignancies treated by reduced-intensity conditioning allogeneic transplants. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
